INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Conditions:   Ovarian Cancer;   Bladder Cancer;   Non Small Cell Lung Cancer;   Squamous Cell Carcinoma of Head and Neck;   Triple Negative Breast Cancer;   Castration Resistant Prostate Cancer;   Colorectal Cancer;   Gastric/ Gastroesophageal Junction;   Hepatocellular Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Squamous Carcinoma of the Anal Canal
Interventions:   Drug: INCB106385;   Drug: INCMGA00012
Sponsor:   Incyte Corporation
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 10, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments